Last edition
News about "precision oncology"
Evexta Bio, Roche Partner to Evaluate Novel Breast Cancer Combination Therapy
Evexta Bio has entered a clinical collaboration with Roche to evaluate its investigational therapy rupitasertib in combination with giredestrant for the treatment of advanced ER+, HER2-, ESR1-mutated breast cancer.
Precision Oncology | 05/08/2026 | By News Bureau
PD-L1 IHC 22C3 pharmDx gains CE-marked indication to identify eligible patients with epithelial ovarian, fallopian tube and primary peritoneal carcinoma for pembrolizumab treatment.
Precision Oncology | 27/07/2026 | By News Bureau
Hikma Welcomes FDA Approval of Guardant360 Liquid CDx, Expanding Precision Cancer Diagnostics
The FDA-approved Guardant360 Liquid CDx enables advanced cancer biomarker testing through a simple blood draw, supporting faster and more precise treatment decisions.
Precision Oncology | 25/06/2026 | By News Bureau | 109
Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.
Precision Oncology | 23/06/2026 | By News Bureau | 201
Sophia Genetics Signs MoU with Memorial Sloan Kettering Cancer Center
Sophia Genetics has signed a strategic collaboration Memorandum of Understanding (MoU) with Memorial Sloan Kettering Cancer Center to establish a next-generation precision medicine hub.
Precision Oncology | 08/06/2026 | By News Bureau | 159
The Colorectal Cancer Alliance and the Global Coalition for Adaptive Research have partnered to launch KLEOS, a pioneering adaptive clinical trial platform designed to accelerate the development of new therapies for colorectal cancer and improve patient outcomes.
Precision Oncology | 01/06/2026 | By News Bureau
Chugai Secures World's First Tumour-Agnostic Approval for ALK Inhibitor Alecensa in Japan
Chugai Pharmaceutical has received regulatory approval in Japan for the expanded use of Alecensa (alectinib) in advanced or recurrent ALK fusion-positive solid tumours, marking the world’s first tumour-agnostic approval for an ALK inhibitor.
Precision Oncology | 19/05/2026 | By News Bureau | 177
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
Precision Oncology | 12/05/2026 | By News Bureau | 256
Illumina, Labcorp Expand Partnership to Advance Precision Oncology
Illumina and Labcorp have expanded their collaboration to strengthen precision oncology through wider use of next-generation sequencing (NGS) technologies.
Precision Oncology | 20/03/2026 | By Darshana | 190
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy